Using plasma proteomics to understand Alzheimer’s and other brain diseases
Using plasma proteomics to understand Alzheimer’s and other brain diseases
The plasma proteome presents a goldmine of information that can be used to develop diagnostic tests and identify novel drug targets. In this webinar, our expert speaker Dr. Keenan Walker describes his research into understanding the proteins, protein networks and biological pathways involved in age-related neurodegenerative diseases and vascular cognitive impairment.
Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebrospinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.
Learn about:
- Proteins most strongly implicated in dementia risk
- How combining proteomics with neuroimaging to provide new insights into cerebral small vessel disease
- The process of nominating potentially casual proteins and genetically validating biomarkers
Keenan Walker, PhD
Chief, Multimodal Imaging of Neurodegenerative Disease (MIND)
National Institute on Aging
Keenan Walker, PhD, is an investigator at the National Institute on Aging Intramural Research Program and Chief of the Multimodal Imaging of Neurodegenerative Disease (MIND) unit. Dr. Walker’s current research program focuses on understanding the role of abnormal immune function in Alzheimer’s disease and late-life cognitive decline.
Using plasma proteomics to understand Alzheimer’s and other brain diseases
A presentation by Keenan Walker, PhD
More webinars
WebinarBoutique Webinar Aptamers with protein-like side chains as a versatile tool for high-content proteomics
Proteins, encoded in 20,000 genes in humans, do much of the work in biology. Measuring proteins, which change in response to various perturbations and represent targets for almost all drugs, offers insights about the health status of an organism. Since proteins operate in complex networks rather than in isolation, measuring multiple proteins simultaneously offers richer insights compared to single protein measurements.
WebinarUsing Proteomics To Advance Understanding of Alzheimer’s Disease
Limited understanding due to its complex pathophysiology and lack of definitive biomarkers currently constrains the diagnosis and treatment of Alzheimer’s disease (AD). But new research is uncovering dynamic brain changes during Alzheimer’s progression, offering potential therapeutic targets. This webinar explores how proteomics and systems biology can be integrated to elucidate AD pathology.
WebinarPredictive modeling and reliable biomarker discovery in clinical omics studies
High-content omic technologies coupled machine learning methods have transformed the biomarker discovery process. However, the translation of computational results into scalable clinical biomarkers remains challenging. A rate-limiting step is the rigorous selection of reliable biomarker candidates among a host of biological features. Drawing examples from real-world clinical omics studies, I will introduce Stabl, a general machine learning framework that identifies a sparse, reliable set of biomarkers by integrating noise injection and a data-driven signal-to-noise threshold into multivariable predictive modeling.